JOBS Jolt 3.0?

Assessing the benefits of JOBS 3.0 for biotechs looking to go public

The latest iteration of the JOBS Act could make it easier for biotechs to go public -- and raise more money more quickly -- but that doesn’t necessarily mean the quality of the IPO queue will be diluted.

The House of Representatives voted 406-4 on Tuesday to pass the JOBS and Investor Confidence Act of 2018, or JOBS Act 3.0, a collection of 32 bills that

Read the full 660 word article

User Sign In